Established therapeutic approaches for patients with HR-positive BC typically include ovarian suppression (via GnRH agonists or surgical oophorectomy), AIs, tamoxifen (selective estrogen receptor modulator—SERM), or fulvestrant (selective estrogen receptor degrader—SERD), alone or in various combinations depending on menopausal status and risk [30]. Here, ESR1 is linked to breast cancer.